Advanz Seeks To Build On European Platform
Correvio And UCB Deals Position Firm For Future Growth
Advanz Pharma recently struck two major deals that have expanded its presence in Europe and bolstered its portfolio. In an exclusive interview with Generics Bulletin, CEO Graeme Duncan explains how the firm plans to build on these moves to make the most of its enhanced platform.
You may also be interested in...
Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.
With a clear plan to move on niche and differentiated generics, complex specialty and value-added medicines, Advanz Pharma has agreed to buy debt-ridden Correvio Pharma and the rights to a portfolio from UCB, at the same time as shareholders opted to move to delist the company’s shares.
In a move expected to unlock operational and cost efficiencies, Advanz Pharma is moving its legal and tax domicile to Jersey, close to its strategic focus on western European markets.